Meyka Pro banner
Scilex Holding Company

Scilex Holding Company Fundamental Analysis (NASDAQ: SCLXW)

SCLXWNASDAQ
HealthcareDrug Manufacturers - General
$0.10
$0.01(17.51%)
U.S. Market opens in 19h 14m

Scilex Holding Company Fundamental Analysis (NASDAQ: SCLXW)

Scilex Holding Company (NASDAQ: SCLXW) shows weak financial fundamentals with a PE ratio of -0.08, profit margin of -14.15%, and ROE of 1.90%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.

Key Strengths

PEG Ratio0.00

Areas of Concern

ROE1.90%
Operating Margin-9.04%
Cash Position2.13%
Current Ratio0.07
We analyze SCLXW's fundamental strength across five key dimensions.

The stock receives a Fundamental Health Score of -1276.7/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.

Fundamental Health Score

F
-1276.7/100

We analyze SCLXW's fundamental strength across five key dimensions:

Efficiency Score

Weak

SCLXW struggles to generate sufficient returns from assets.

ROA > 10%
-1.76%

Valuation Score

Excellent

SCLXW trades at attractive valuation levels.

PE < 25
-0.08
PEG Ratio < 2
0.00

Growth Score

Weak

SCLXW faces weak or negative growth trends.

Revenue Growth > 5%
N/A
EPS Growth > 10%
N/A

Financial Health Score

Moderate

SCLXW shows balanced financial health with some risks.

Debt/Equity < 1
-0.31
Current Ratio > 1
0.07

Profitability Score

Weak

SCLXW struggles to sustain strong margins.

ROE > 15%
189.81%
Net Margin ≥ 15%
-14.15%
Positive Free Cash Flow
No

Key Financial Metrics

Is SCLXW Expensive or Cheap?

P/E Ratio

SCLXW trades at -0.08 times earnings. This suggests potential undervaluation.

-0.08

PEG Ratio

When adjusting for growth, SCLXW's PEG of 0.00 indicates potential undervaluation.

0.00

Price to Book

The market values Scilex Holding Company at -0.11 times its book value. This may indicate undervaluation.

-0.11

EV/EBITDA

Enterprise value stands at 0.14 times EBITDA. This is generally considered low.

0.14

How Well Does SCLXW Make Money?

Net Profit Margin

For every $100 in sales, Scilex Holding Company keeps $-14.15 as profit after all expenses.

-14.15%

Operating Margin

Core operations generate -9.04 in profit for every $100 in revenue, before interest and taxes.

-9.04%

ROE

Management delivers $1.90 in profit for every $100 of shareholder equity.

1.90%

ROA

Scilex Holding Company generates $-1.76 in profit for every $100 in assets, demonstrating efficient asset deployment.

-1.76%

Following the Money - Real Cash Generation

Operating Cash Flow

Scilex Holding Company generates limited operating cash flow of $-21.55M, signaling weaker underlying cash strength.

$-21.55M

Free Cash Flow

Scilex Holding Company generates weak or negative free cash flow of $-22.08M, restricting financial flexibility.

$-22.08M

FCF Per Share

Each share generates $-2.60 in free cash annually.

$-2.60

FCF Yield

SCLXW converts -40.98% of its market value into free cash.

-40.98%

Financial Ratios Analysis

Valuation Ratios

P/E Ratio

Price to earnings ratio

-0.08

vs 25 benchmark

PEG Ratio

Price/earnings to growth ratio

0.00

vs 25 benchmark

P/B Ratio

Price to book value ratio

-0.11

vs 25 benchmark

P/S Ratio

Price to sales ratio

1.38

vs 25 benchmark

Financial Health

Debt/Equity

Total debt to shareholders' equity

-0.31

vs 25 benchmark

Current Ratio

Current assets to current liabilities

0.07

vs 25 benchmark

Efficiency Ratios

ROE

Return on equity percentage

1.90

vs 25 benchmark

ROA

Return on assets percentage

-1.76

vs 25 benchmark

ROCE

Return on capital employed

1.10

vs 25 benchmark

How SCLXW Stacks Against Its Sector Peers

MetricSCLXW ValueSector AveragePerformance
P/E Ratio-0.0831.31 Better (Cheaper)
ROE189.81%526.00% Weak
Net Margin-1414.57%21528.00% Weak
Debt/Equity-0.310.53 Strong (Low Leverage)
Current Ratio0.075.62 Weak Liquidity
ROA-176.33%-105.00% (disorted) Weak

SCLXW outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.

Historical Growth Performance

5-Year Growth Trajectory

This section reviews Scilex Holding Company's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.

Revenue CAGR

N/A

Industry Style: Defensive, Growth, Innovation

EPS CAGR

N/A

Industry Style: Defensive, Growth, Innovation

FCF CAGR

N/A

Industry Style: Defensive, Growth, Innovation

Fundamental Analysis FAQ